COMMUNIQUÉS West-GlobeNewswire

InnoCare Announces Approval of Orelabrutinib in Australia
27/05/2026
BEIJING, May 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that orelabrutinib (HIBRUKA ® ) has [...]
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
27/05/2026
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed [...]
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
27/05/2026
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
Invivyd to Participate in Upcoming Investor Events
27/05/2026
NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference in New York [...]
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
27/05/2026
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, [...]
L’Association canadienne de dermatologie, en partenariat avec Mélanome Canada, offrira des dépistages gratuits du cancer de la peau sur la Colline du Parlement
27/05/2026
Cet événement a pour but de souligner l’importance vitale du dépistage précoce du cancer et d’appeler à un meilleur accès aux soins dermatologiques partout au Canada OTTAWA, Ontario, 27 mai 2026 (GLOBE NEWSWIRE) -- [...]
Agomab Announces Results of Annual General Meeting
27/05/2026
Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM [...]
Canadian Dermatology Association in Partnership with Melanoma Canada Offer Free Skin Cancer Screenings on Parliament Hill
27/05/2026
The event highlights the life-saving importance of early detection and calls for improved access to dermatological care across Canada OTTAWA, Ontario, May 27, 2026 (GLOBE NEWSWIRE) -- As skin cancer rates continue to [...]
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
27/05/2026
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair’s [...]
Korro to Present at the 2026 Jefferies Global Healthcare Conference
27/05/2026
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
Transforming Rural Health Care Through a First-of-its-Kind Collaborative
27/05/2026
A study designed to address rural pharmacy deserts by bringing pharmacy services directly into the home BLOOMINGTON, Minn., May 27, 2026 (GLOBE NEWSWIRE) -- Ōmcare and PharMerica are proud to announce the launch of the [...]
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
27/05/2026
Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant [...]
Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving Global South
27/05/2026
Rebrand to SkyAI, Inc. to reflect evolution of the business to build a global agentic finance platform Opened operational headquarters in Hong Kong, a global hub for financial technology innovation and a base for [...]
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
27/05/2026
Investigational Oral Candidate JOTROL ™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: [...]
Satellos to Participate in Upcoming Investor Conferences
27/05/2026
TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat [...]
HNL Lab Medicine Receives Accreditation from the College of American Pathologists
27/05/2026
ALLENTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) following a recent on-site inspection [...]
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
27/05/2026
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
27/05/2026
MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will [...]
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
27/05/2026
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart [...]

Pages